Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Innovative Imperial spin-out biopharmaceutical company teams up with BioVectra

08.08.2007
PolyTherics, a biopharmaceutical spin-out company from Imperial College London and the London School of Pharmacy, today announced that it has signed a manufacturing and bilateral representation agreement with BioVectra dcl, a Canadian biopharmaceutical company that supplies specialty chemicals and contract manufacturing services to the pharmaceutical and biotechnology industry.

The agreement, which follows hard on the heels of PolyTherics’ recent successful fundraising of over £2 million, will see BioVectra manufacturing high quality cGMP MPEG reagents to support clients’ clinical development of PolyTherics’ novel PEGylation technology. BioVectra will also market the PEGylation technology to its client base in North America.

PolyTherics has developed patent-protected proprietary technologies and expertise in the modification of drugs to improve their performance. The Company’s innovative PEGylation technology, known as TheraPEG, can extend the half-life of novel and existing protein drugs. The TheraPEG approach produces an improvement in biological activity and a higher yield than the existing PEGylation technologies. This means that drugs, such as Interferon, stay active in the body for longer, enabling longer periods between doses. Patients can therefore be treated less often, with fewer side-effects and at lower cost.

The market for traditional PEGylation has expanded considerably and PolyTherics’ TheraPEG technology is positioned both to address existing markets and open new markets, particularly in the antibody field. PolyTherics already has revenue-generating development contracts in place with several companies and is in discussion with a number of other parties.

Dr Keith Powell, CEO of PolyTherics, said: “We are delighted to have signed this agreement with BioVectra, who offer access to specialist custom polymer chemistry capabilities, a patented MPEG purification process and scaled manufacturing systems –the key components that are needed to support clients of our TheraPEG™ technology.

“We are currently in discussion with a number of biogeneric and pharmaceutical companies in Europe and the USA and there is significant interest in downstream applications for our TheraPEG technology. This agreement with BioVectra means that we can work with a highly competent manufacturer who will supply the highest quality MPEGs to meet our clients’ needs and comply with FDA standards. So we now have the tools to take our TheraPEG™ technology from the laboratory into the feasibility testing and manufacturing stages.”

Stephen Ball, Business Development Representative for BioVectra, said: “We are pleased to be working with PolyTherics to support the development of their innovative and important site specific TheraPEG technology. We look forward to deploying our capabilities in the manufacturing of high quality cGMP MPEG reagents to assist PolyTherics’ clients through clinical development of therapeutic proteins into post approval commercialization.”

Dale Zajicek, Chief Operating Officer of BioVectra, said: “We remain committed to supporting our PEGs business initiatives with technology that creates true value for our customers and their patients. The PolyTherics agreement is a clear example of this commitment.”

Margaret Henry | alfa
Further information:
http://polytherics.co.uk

More articles from Life Sciences:

nachricht The birth of a new protein
20.10.2017 | University of Arizona

nachricht Building New Moss Factories
20.10.2017 | Albert-Ludwigs-Universität Freiburg im Breisgau

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Terahertz spectroscopy goes nano

20.10.2017 | Information Technology

Strange but true: Turning a material upside down can sometimes make it softer

20.10.2017 | Materials Sciences

NRL clarifies valley polarization for electronic and optoelectronic technologies

20.10.2017 | Interdisciplinary Research

VideoLinks
B2B-VideoLinks
More VideoLinks >>>